SOURCE: MedaSorb Technologies Corporation

April 11, 2007 07:30 ET

MedaSorb Appoints Dr. Edward R. Jones, MD, MBA to Board of Directors

MONMOUTH JUNCTION, NJ -- (MARKET WIRE) -- April 11, 2007 -- MedaSorb Technologies Corporation (OTCBB: MSBT) announced today the appointment of Dr. Edward R. Jones, MD, MBA to its Board of Directors, effective April 9, 2007. Dr. Jones is an attending physician at the Albert Einstein Medical Center and Chestnut Hill Hospital as well as Clinical Professor of Medicine at Temple University Hospital.

Al Kraus, President and CEO of MedaSorb Technologies Corporation, said, "Bringing Dr. Jones on board is an affirmation of our commitment to take our CytoSorb™ device through testing to market. His valuable experience with the research community and management of medical research programs will be a great asset to us." Dr. Jones is a practicing nephrologist as well as medical director of a dialysis facility for Fresenius Medical Care. He teaches renal pathophysiology at Temple and at the Philadelphia College of Osteopathic Medicine.

Dr. Jones is a highly respected member of the renal research community. He has published or contributed to publishing 30 chapters, articles, and abstracts on the subject of treating kidney-related illnesses. He is a sixteen-year member of the Renal Physicians Association, the Philadelphia County Medical Society and a past president of the National Kidney Foundation of the Delaware Valley. Dr. Jones has been elected as the next President of the Renal Physicians Association starting in 2008.

About MedaSorb

MedaSorb Technologies Corporation is a medical device company headquartered in Monmouth Junction, New Jersey. MedaSorb has developed and is preparing to commercialize a blood purification technology that efficiently removes toxic compounds from circulating blood. MedaSorb's initial products, CytoSorb™ and BetaSorb™, are known medically as hemoperfusion devices and incorporate proprietary adsorbent polymer technology. MedaSorb believes that potential healthcare applications for its products include: adjunctive treatment of sepsis, prevention of damage to organs donated for transplant prior to organ harvest, prevention of post-operative complications of cardiac surgery, and the short and long-term treatment of kidney failure.

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. MedaSorb Technologies Corporation believes that its primary risk factors include, but are not limited to: obtaining government approvals including required FDA approvals; ability to successfully develop commercial operations; dependence on key personnel; acceptance of the Company's medical devices in the marketplace; the outcome of pending and potential litigation; compliance with governmental regulations; reliance on research and testing facilities of various universities and institutions; the ability to obtain adequate financing in the future when needed; product liability risks; limited manufacturing experience; limited marketing, sales and distribution experience; market acceptance of the Company's products; competition; unexpected changes in technologies and technological advances; and other factors detailed in the Company's Current Report on Form 10KSB filed with the SEC on March 30, 2007, which is available at

Contact Information